论文部分内容阅读
目的:探讨绝经前妇女中重度周期性乳痛症应用托瑞米芬治疗的有效性和安全性。方法选择2012年4月至2013年1月滨州市中心医院结防院收治的112例绝经前妇女周期性乳痛症患者作为研究对象,并采用托瑞米芬治疗,40 mg/d,晚餐后服用,疗程包括3个月经周期。比较治疗前后乳痛改善情况、性激素变化情况、不良反应发生情况及子宫内膜厚度。结果治疗3个月经周期后,112例患者中83例(74.10%)患者治疗有效,乳痛评分平均降低(58.85±22.96)%。治疗后患者孕酮、雌二醇、促黄体生成素和促卵泡激素水平均有一定程度提升,但与治疗前比较差异无统计学意义(P>0.05)。治疗前后子宫内膜厚度以及子宫内膜厚度≥5 mm例数比较差异无统计学意义(χ2=0.254,P>0.05)。治疗后112例患者中25例(22.32%)潮红多汗,发生率高于治疗前,差异有统计学意义(χ2=13.515,P0.05).Endometrial thickness and the number of endometrial thickness≥5 mm had no significant difference compared to before(χ2=0.254,P>0.05). 25 cases(22.32%) of 112 cases patients occurred flushing hyperhidrosis,the incidence was higher than that of before,the difference was significant(χ2=13.515,P<0.05). Conclusion Toremifene could greatly improve clinical symptoms of moderate-severe cyclical mastalgia,and has few influence on sex hormone and adverse reactions,with high efficiency and safety.